Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Flax is Dentist. He is 70
Flax has been involved in NPHC since at least 2004.
https://www.sec.gov/Archives/edgar/data/1119643/000118206305000028/xslF345X03/flaxform4_ex.xml
NPHC last filed a 10-Q for the 09/30/2022 Quarter.
Why did Deitsch stop filing and why hasn't Flax started filing. Flax is the former CEO of NPHC.
From the settlement:
"Permanently enjoin Defendant Deitsch from committing violations of the federal securities laws that the SEC has alleged in this case... thereunder; impose a three-year officer-and-director bar on Deitsch... and impose a three-year penny-stock bar on Deitsch.
After the 3 year ban Deitsch has to apply to the SEC to be involved in penny stocks as a officer, director...
And that is unlikely to happen.
IG
No, but keep looking for one. FWIW.... there were 2 trades.
one for 5 shares and the other for 186 shares.
We're gonna be rich!!!
on this day 9/11 we have a trade for 191 , LOL
Is this some kind of a message here?
RSI38
NPHC
The settlement has been approved by the judge. Now let’s see if the company will put out a statement explaining to us how they intend to move forward.
I was reffering to the time that is needed to get this company fully current on all of their paperwork.
The question is did the new ceo start this process of it is just sitting there?!!
Time will tell
RSI38
RS138, What process to start?
I am sticking to my earlier forecast of 18 Months to clear all.
When will this process start is something the new ceo knows
And maybe Ricky, LOL
Early 2026 ?
RSI38
You missed nothing, I was checking the board for a pulse.
Did I miss the news? You must be joking.
Nice to see all this news from the company...............................
Testing, 1 2 3 Testing.
Deitsch is the reason investors lost money.
Deitsch is banned from being involved from any involvement in securities in any way.
One huge problem is that Deitsch owns so many Shares.
IG
First they have to remove the CE - and get current on their filings.
I don't know much about the new CEO but it seems he has some baggage.
These scam shells are passed around and you just hope the new group is more competent that Deitsch. And try to catch a new trend - but always remember NPHC will always be a scam. That doesn't mean you can't profit.
Play the price action and always take profits.
And never believe the company hype.
Good luck!
Not me Risk.
I think Rik is pretty much toast with this company. The pressure is now on the new ceo who took over this failed company.
My guess is that it may come back up in about 18 months or so... There is so much to do here to
GLTA
RSI38
Need to use one of the offshore brokers.
No, why would I communicate with the janitor?
Sam, RS13 any communication with Rik? Any plans for this ?
k9narc, You are correct. I tried it and it did not allow any buying. I suppose we can sell there.
There may be a brokerage that allows it, but from everything I've seen, they are few and far between.
"I've pretty much tried opening up a brokerage account with nearly every US based broker, and so far no one allows traders to buy from the Expert Market. I do meet the regulatory requirement for brokers to show me quotes, but none will. Technically, anyone is allowed to buy, but the brokerage could get in trouble by facilitating the trade to the wrong person. This seems a bit crazy to me since I'm allowed to shovel all of my money into lottery tickets and slot machines, but cannot speculate on companies on the Expert Market I believe can get out."
"It's a highly restricted market tier on OTC Markets. A bunch of dark companies moved there in 2021, previously retail investors were allowed to trade them. Now, you have to be qualified, which basically means only institutional and accredited investors can be shown quotes. Technically, legally anyone is allowed to buy if they can figure out how; however, the brokerage can get in trouble if they allow you to."
"I have all my accounts with Schwab which allows the following based on SEC status and OTC Markets tier:
I can buy or sell online
SEC Registered
OTCQB
OTCQX
Pink Current Information
Pink Limited Information
I can sell only. No buys allowed
Expert Market
Grey Market
Those last two bullet points are the non-filers I cannot buy anymore. "
Good Luck
I thought Schwab was trading it before.
I think Canadian accounts still trade it.
In the US you have to head to the expert market.
"Warning! This security is traded on the Expert Market
The Expert Market® serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for quoting on the Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting."
Good luck
Can one buy this if possible?
You are such a clown - you still don't understand that you can't short a CE stock.
As it turned out everything you posted was proven to be not true - you were just a pumping clown. Everything I posted about the NPHC scam was proven to be true.
How many times did you post the the SEC was going drop the case or that Deitsch was kicking the SEC's ass.
I always thought you were Deitsch.
"2.5 million volume in nphc shows the short market makers are covering cause they know whats coming. You can also tell when the shorts are desperate becauae they make up shit to covince people to sell into them."
That shows you are clueless about shorting.
IG
Yep, but it was frivolous according to some.
Of course he's still in charge.
Hmmm, so it was frivolous. Deitsch had problems with the FDA - he was busted by two 2 brokerage firms for manipulating the price and - "As to Deitsch, the consent judgment also included a three-year officer and director bar and a three-year penny stock bar."
Deitsch was the CEO for over 20 years and he never accomplished anything of value.
Look at all of the false and misleading information he issued in press releases.
If the CE was to be removed Deitsch should have been completely removed himself from the company.
But Deitsch still controls the company.
IG
The SEC has issued a report date of June 19th for any updated filings.Found it on Stocktwits.
More Snake Oil Please! The pump is dry.
Sure it is... As of now ALL of the negatives are of the past now.
We have a clean slate here but the new leader must start off right by:
Getting Current
Addressing company products and such
Do not over promise on goals...
If the above happens this is a .03 stock at least
RSI38
The past story sucks, and it still carries a CE.
Positive? Maybe, but a lot of work needs to be done to get current.
Is this positive for us going forward? Not sure of the past story here..
Glad that frivolous and baseless law suit is over........
LITIGATION RELEASES
Nutra Pharma Corp. et al
U.S. SECURITIES AND EXCHANGE COMMISSION
Litigation Release No. 26007 / May15, 2024
Securities and Exchange Commission v. Nutra Pharma Corp. et al, No. 2:18-cv-5459 (E.D.N.Y filed Sept. 28, 2018)
SEC Obtains Final Judgments Against Florida Microcap CEO and Consultant for Fraud
On May 13, 2024, the U.S. District Court for the Eastern District of New York entered final consent judgments against Erik (“Rik”) Deitsch, the former CEO of microcap issuer Nutra Pharma Corporation (“Nutra Pharma”), and Sean McManus, a consultant for Nutra Pharma, enjoining them from violating certain provisions of the federal securities laws, ordering disgorgement and civil monetary penalties, imposing penny stock bars, and as to Deitsch, imposing an officer-and-director bar.
According to the SEC’s complaint, Nutra Pharma, a microcap issuer that purports to make pain relief drugs with cobra venom, and Deitsch, issued or posted a series of press releases that materially misled investors. The releases allegedly implied, among other things, that Nutra Pharma had engaged a company to distribute its product internationally, when it had not, and that Nutra Pharma had expanded and upgraded its cobra farm facilities, when it did not own those facilities or the cobras and there were no expansions or upgrades at that time. Nutra Pharma publicized many of these press releases while Nutra Pharma and Deitsch allegedly engaged in an unregistered distribution of its securities to retail investors. In addition, on multiple occasions, Deitsch allegedly engaged in manipulative trading to stabilize or raise Nutra Pharma’s stock price and create the appearance of active trading. Further, Nutra Pharma and Deitsch allegedly failed to make numerous required filings, including ones about the company’s sales of unregistered securities and ones about Deitsch’s beneficial ownership of the company’s securities. McManus allegedly made misrepresentations to investors while acting as an unregistered broker.
The SEC’s complaint charged Deitsch with violating Sections 5(a) and (c) and 17(a) of the Securities Act of 1933 (“Securities Act”) and Sections 9(a)(2), 10(b), 13(a), 13(d), and 16(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rules 10b-5, 13a-14, 13d-2, and 16a-3 thereunder. The Commission further alleged he aided and abetted Nutra Pharma’s violations of Section 17(a) of the Securities Act and Sections 10(b) and 13(a) of the Exchange Act and Rules 10(b)-5, 13a-11, and 13a-13 thereunder. McManus was charged with violating Section 17(a) of the Securities Act and Sections 10(b) and 15(a) of the Exchange Act and Rule 10b-5 thereunder.
On August 31, 2022, the court granted the Commission summary judgment on its claims that Deitsch violated Sections 5(a) and 5(c) of the Securities Act and Sections 13(d) and 16(a) of the Exchange Act and Rules 13d-2 and 16a-3 thereunder. The Commission dismissed the aiding and abetting charges against Deitsch, and on March 19, 2024, the Court entered partial consent judgments against Deitsch and McManus in which they agreed, without admitting or denying the allegations, to be permanently enjoined from violations of the charged provisions. As to Deitsch, the consent judgment also included a three-year officer and director bar and a three-year penny stock bar.
On May 13, 2024, the Court entered final consent judgments against Deitsch and McManus. Deitsch was ordered to pay $44,046.28 in disgorgement and $5,013.49 in prejudgment interest thereon, as well as $30,000 in civil penalties. McManus was ordered to pay $5,500 in disgorgement and $625.03 in prejudgment interest thereon, as well as $5,500 in civil penalties and agreed to a two-year penny stock bar.
The SEC’s litigation is being handled by Lindsay S. Moilanen, Lee Greenwood, Rusty Feldman, and Karolina Klyuchnikova of the New York Regional Office and is being supervised by Daniel Loss and Sheldon L. Pollock.
https://www.sec.gov/litigation/litreleases/lr-26007
I agree with most you said, but I put my money up and expect a return. Some investments are more risky than others.
When this will hit pennies?
Lol....
7.6 billion shares out
Highest volume last year is 8 million
Highest volume last 3 years 70 million.......
Durrr
Dont be mad that your buying back your nphc short position. Ive seen that volume lately.
I always thought Happy Horsey Feet would have been a better name than Equine pain Away. More catchy. Just imo. Luxury Feet was targeted towards women or whatever wearing high heels lol. Ten total sales for both collectively, maybe.
You need to understand that the OTC is for trading not investing - that will help you from losing so much money.
"Gambling and speculating are investing. You put money up and see if you lose or gain when you get out. I call it investing and you can go ahead and think the way you do."
That is what those that go to a Casino and plays the penny slots while dreaming of a Villa in the Caribbean.
You can't become emotionally attached to OTC stocks - and you have to be disciplined - anyone that gambles in the stock market 8s going to lose.
Plus, you have to know when to cut your losses smart investors use around 8%.
But you thought NPHC was a real company and it wasn't.
IG
You were pumping since 2009 - and spewing nonsense about NPHC being shorted even when the price was $0.0001 - proving you were clueless about shorting.
You posted many times that Deitsch kicked the SEC'S ass and that didn't work out very well.
Now NPHC is on the Expert Market market and you have lost your entire investment.
"Not a chance nphc goes to gray market. They filed their 10q. They dont have any outstanding financial filings. just absurd to even think that they would go to gray. mark this post."
The Expert Market is the new Grey market.
Here is something you posted dozens of times and I always got a good laugh.
""cngreen
Friday, 07/16/2021 3:48:03 PM
Here is what's coming from Deitsch and NPHC
Multiple Sclerosis Trials
Government Grants for validation of NPHC Nerve Agent Counter measure
Adding to NPHC's 21 Patents
Additional Social Media Endorsements
New Products from NPHC
Here is what Deitsch the CEO has done for NPHC in 19 years:
Added Many patents and trademarks to Nutra's portfolio
Clinical Trials in Multiple Phases
1. Multiple Sclerosis Trials
2. Herpes Simplex Infections 1 & 2 Trials
3. Adrenomyeloneuropathy Trials
4. HIV Trials
5. Amyotrophic Lateral Sclerosis Trials
6. Rheumatoid Arthritis Trials
7. Pain Trials
Products launched and brought to Market
1. Cobroxin
2. Nyloxin
3. Pet Pain Away
4. Equine pain Away
5. Luxury Feet
Published Research
http://receptopharm.com/drug_development/published_research.php
https://www.nutrapharma.com/research
Increased Sales on Amazon and Walmart
RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis
Huge personal loans from Deitsch to NPHC tells me the CEO knows and believes in NPHC"
And you bought into all of the Deitsch BS.
Damn, I have never seen anyone as wrong as you about a stock.
IG
Expecting big things here. I am fully invested.
So how's your "investment" doing? Still a rotten turd after your phone call with Rik? Seeing as the CE has yet to be removed, I'd say this rotten turds been flushed. Won't be the last one either, learn to actually invest or pay someone to do it for you while you speculate with casino money as the house always wins
Just cause you think me calling you hopeless is childish doesn't invalidate my statement. Rik is a con artist, you fell for it and still refuse to open your eyes lol. Where's that DTRA answer?? Live and learn kiddo, or forever be hopless
Calling me hopeless is childish.
You can't really be serious?? So by going to the casino to gamble people are "investing".........? And the house always wins lol. Tried throwing ya a bone or two but your hopeless.
Gambling and speculating are investing. You put money up and see if you lose or gain when you get out. I call it investing and you can go ahead and think the way you do.
You clearly don't know the difference between investing, gambling and speculating. Perhaps read some books on market cycles? I have a ton of audiobooks and podcasts I listen too almost daily. Give Mark Douglas trading in the zone a listen. Short sweet and easy to follow. If you want to invest, read rule one investing by Phil town. He shows you how to value a company, project future price and and what price is safe to buy all based off 10 years of financials and some math. A few years ago I went thru all my stocks and none were anywhere near close to his margin of safety buy prices. One was at $80 and had a buy of mid 20s if I remember right. That was coherent/iivi. Ya know what, took about a year and it dropped within literally a few dollars of the price I was shown to calculate. You can probly go find me saying that on that board as it isn't frequented. Don't believe hype. Think for yourself or search for info and how to understand it. Iglow posts a bunch of stuff over my head, I too once though he was just a "basher" of NPHC. Some people actually try helping others or make them second guess the motives of the pumpers. Goodluck and hope you learn to invest
Like I said, you confirm.
You may call it trading on the penny stocks, but if you put your money down on anything and expect a return it actually is investing. Face it you are happy to make yourself feel you are smarter than most. That is why you post and do not care if others lose money here who already invested. You are fraudulent in your comments regarding us investors that are stuck in your opinion.
Obviously touched a nerve with you.
You should take some Nyloxin, it can help with your pain.
Rowdychumpion, this is a proven point. I stand guilty of your claims lol.
Followers
|
499
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
64422
|
Created
|
05/04/06
|
Type
|
Free
|
Moderators |
Nutra Pharma Corp. (OTC: NPHC) is a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases. Nutra Pharma, through its RectoPharm subsidiary, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process ReceptoPharm is developing technologies for the production of drugs for HIV and multiple sclerosis (MS), and also offers small and start-up biotech companies a full range of contract research services.
Investment Highlights
Corporate Strategy
Nutra Pharma's over-the-counter (OTC) products allow the company to achieve profitability and fund longer-term clinical trials in the therapeutic area. The therapeutics address a market size of > $10 billion, while the OTC products segment addresses a market size of $200 million - $500 million.
Reducing Risk
Nutra Pharma's strategy aims to optimize risk and return. At present, the company has a line of OTC products that bring in cash. This revenue will not only help fund development of the company's therapeutic line but, since sales of the OTC line and therapeutic line are uncorrelated, will result in a smoother revenue stream. By having what is, essentially, two businesses under one roof, Nutra Pharma mitigates risk to shareholders.
Revenue in the Short-term from OTC products
The OTC line comprises a number of analgesics. In October 2009, Nutra Pharma launched its first, called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, the company launched its second consumer product, called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin.® And in December 2014, it launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. Nyloxin is currently being distributed both domestically and internationally via network marketing through the nationwide distributor Lumaxa.
Maximizing Return with a High-Value Therapeutic Line
Through its wholly owned subsidiary, ReceptoPharm, Inc., Nutra Pharma conducts drug discovery research and development activities. Nutra Pharma's R&D pipeline consists of several novel therapies in various stages of development to prevent and or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, and rheumatoid arthritis (RA). And the company is pursuing, aggressively, regulatory approval for these treatments.
Nyloxin
Nyloxin is an anti-inflammatory, non-toxic, non-narcotic, non-addictive, non-steroidal analgesic designed for chronic pain relief. It was first launched as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, arthritis pain and pain from repetitive stress.
Since the beginning of 2014, it has been moved by the over 3,000 distributors in the Lumaxa network. Nutra Pharma is approved to distribute Nyloxin in India and is currently negotiating with large distributors throughout the region. Nutra Pharma is also working with several potential distributors in China and expects orders in India and China in the near future.
Nyloxin is clinically proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic pain. It is safe, non-narcotic and non-addictive, and does not impair cognitive function. Nyloxin is available in three strengths and 12 SKUs. In Regular Strength, Nyloxin is offered as an oral spray, a topical roll-on, and a topical gel. These same three preparations are offered in Extra Strength. The company also plans a 'Military Strength' Nyloxin for U.S. government buyers and military personnel.
Nyloxin Advantage
Jeff Gottfurcht is the first person in the world with rheumatoid arthritis to scale Mount Everest. Jeff reached the summit on May 14, 2011. He took Nyloxin with him as his pain reliever of choice.
Testimonials
Nyloxin Topical Gel I'm a massage therapist I have incorporated Nyloxin into my pain therapies with unbelievable results. I believe in this product so much that I became a distributor just so my clients can live pain free. - Steve Smith | |
Nyloxin Extra Strength Topical Gel I have never written a testimonial before. I have to tell you I am completely amazed at how well this product has worked for me. I have been on hydrocodone for years. Four days after taking this I have not needed it. I truly am shocked at the difference this has made in my pain. I have already reordered! - Elyse Feldberg | |
Nyloxin Oral Spray I am amazed at how well the Nyloxin spray has worked for me. I have had headaches for years, which sometimes turn to migrains. I have done biofeedback, been in the medical care of neurologists, and gone through testings, nothing I have tried has ever gotten rid of my headaches for any length of time, until I tried the Nyloxin spray. I even went to the mountains last weekend at 6,000 feet, for 3 days without a headache the whole time, I don't remember that ever happening. I am sold on this product. - Nancy Leamons |
*Some of the testimonials listed here may be from MyNyloxin Independent Entrepreneurs who may receive compensation which is received based on the sale of Nyloxin products."
Pet Pain-Away
Pets Owned in the U.S.: 95.6 million cats, 83.3 million dogs
The market for pain relief in dogs and cats is more than $200 million.
Millions of pets suffer from acute or chronic pain. While acute pain is a normal sensation triggered in the nervous system to alert your pet of possible injury and the need to take it easy, chronic pain is different, chronic pain persists. Pain signals keep firing in the nervous system for weeks, months, even years.
Historically, pain relief products for pets have been shown to cause other significant healthcare concerns and side effects.
Today, cobra venom is successfully being used for treating various forms of pain, autoimmune and neurological disorders. The Nutra Pharma subsidiary, ReceptoPharm, and other researchers have definitively proven that extracts from cobra venom contain constituents that control pain and inflammation in animals.
Pet Pain Away provides all-natural anti-inflammatory analgesic pain relief that is non-toxic, non-narcotic, non-steroidal and contains no aspirin or acetaminophen. Safe to use on pets, it treats conditions that cause chronic pain in animals.
Current Medical Research of the Available Remedies
Current pain relief products for pets such as NSAIDs (just for dogs) such as Carprofen (Novox or Rimadyl), Deracoxib (Deramaxx), Etodolac (Etogesic), Firocoxib (Previcox), Meloxicam (Metacam ) or Tepoxalin ( Zubrin) have been shown to cause kidney, liver, or digestive problems. Cats do not tolerate NSAIDs of any kind well. The only approved NSAID for cats in the United States is meloxicam and it is only approved for a single post-surgical injection to relieve pain. The dose must be exactly correct for the cat's weight. If it is given longer to cats, it often causes severe kidney damage.
Other medications such as Amantadine, Gabapentin and Tramadol may cause upset stomach, decreased heart rate, panting, and constipation. Veterinarians may prescribe stronger opiates only for a short periods. They usually don't prescribe steroids for pain, as they can have serious side effects. Veterinarians are usually hesitant to utilize pain therapies in companion animals because of the following: significant side effects, including nausea, vomiting, drowsiness, itching, constipation and respiratory depression; buildup of tolerance to analgesic requiring higher dosage over time to experience same effect; addictive properties that include severe withdrawal symptoms.
Therapeutic Pipeline
ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain.
Abbreviations
Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)
RPI-78M
RPI-78M is derived from alpha-cobratoxin (α-CTX) by an oxidative procedure. Alpha-cobratoxin is the primary neuroactive peptide found in the venom of Asiatic cobras, and it represents the single active ingredient in the formulation under investigation. RPI-78M compares favorably with competing products. It lacks measurable toxicity, but is still capable of attaching to and affecting the target site on the cells. This means that patients cannot overdose.
Following years of investigations in humans and animals, it has displayed no serious adverse side effects. Patients experience symptomatic improvements, usually within six months of therapy. RPI-78M is extremely stable and resistant to heat, and so has a long shelf life. The drug's stability has been determined to be over four years at room temperature. It is easy to administer as a daily intramuscular injection (mcg dosing). RPI-78M has completed two trials for its use to treat adrenomyeloneuropathy (AMN). And at present, there are about 300 multiple sclerosis patients on open-label trials with RPI-78M.
RPI-MN
Nutra Pharma has received Orphan Drug Status from the FDA for RPI-78M as a candidate for the treatment of juvenile MS. Nutra Pharma is actively seeking collaborative research partners for early stage trials of RPI-78M in the treatment of juvenile multiple sclerosis (MS). The company has already been in contact with potential researchers, hospitals and sites of care for the purpose of moving forward with phase I/II clinical studies.
Nutra Pharma believes that RPI-78M provides an entirely new approach to the treatment of auto-immune diseases, including MS. As an immuno-modulating agent and not an immunosuppressive, RPI-78M could be a disruptive new drug entity in the autoimmune disease space. In previous open-label studies, RPI-78M has shown consistent symptomatic improvements within a period of less than six months in all stages of MS. The recently received Orphan Drug designation from the FDA allows the company to fast-track efforts through the clinical process. Based on existing clinical experience with RPI-78M, Nutra Pharma is confident that it can receive accelerated approval in a relatively short time-frame (expected in as little as 22-26 months).
RPI-78
Market Opportunity
According to the Centers for Disease Control and Prevention (CDC), there are currently about 1.2 million persons in the United States over the age of 13 who are human immunodeficiency virus (HIV) infected. Over the past 10 years the number of people living with HIV has increased. The incidence of new HIV infections has remained fairly stable, however, at about 50,000 new cases every year. As yet there is no cure for HIV: no compound has been isolated that kills the pathogen. But antiretroviral therapies (ART) can reduce the ability of the virus to reproduce and so keep infection at a level that does not overwhelm the immune system. The World Health Organization (WHO) estimates that, currently, there are about 37 million people worldwide living with HIV. The market size of antiretroviral therapies is estimated to be around $15 billion.
Like HIV, multiple sclerosis (MS) occurs when the immune system malfunctions. MS develops when the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body. The National Multiple Sclerosis Society estimates that about 2.3 million people are affected by MS worldwide. The market size of the MS drug market is about $16.7 billion. Adrenoleukodystrophy (AMN), also known as Schilder's disease and sudanophilic leukodystrophy, is another condition in which the myelin sheath is damaged. The AMN market has the potential to reach $400 million after the launch of an effective treatment. The Herpes Simplex Virus (HSV) affects thousands. According to the CDC, in 2013, some 306,000 persons visited a doctor for the first time in connection with a herpes condition. And the CDC also reports that, in 2007, about 1.5 million people in the U.S. were living with rheumatoid arthritis.
Management
Nutra Pharma is led by a management team comprised of highly experienced and educated professionals with a strong track record of excellence. This leadership is well-equipped to advance Nutra Pharma's therapeutic pipeline and increases distribution of its OTC products internationally.
Rik J. Deitsch - Chairman and Chief Executive Officer
Rik Deitsch holds both a B.S. in chemistry and an M.S. in biochemistry, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Deitsch is the author of two books and is an adjunct professor, teaching several courses for Florida Atlantic University's College of Business and Continuing Education Department.
Stewart Lonky, MD MBA - Director - Audit & Compensation Committees
Stewart Lonky is board certified in internal medicine, pulmonary and critical care medicine. He has published over a dozen articles in the peer-reviewed literature. Stewart is the former chief medical officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA).
Harold H. Rump - Director
Harold Rump holds a B.S. from the United States Naval Academy. He is the former president, and director of Biogenix, Inc., a company involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications.
Garry R. Pottruck, CPA - Director - Chairman, Audit & Compensation Committees
Garry Pottruck is a CPA and financial expert on the NPHC's board of directors. Previously he served as chief accounting officer/controller at Scopas Technology Company, Inc., a NASDAQ-listed, development stage biotechnology research and development organization. He was, also, a principal and manager in the firm Argy, Wiltse & Robinson, PC ("Argy"), headquartered in McLean, Virginia.
Nutra Pharma Corporation | QualityStocks Investor Relations |
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Contact :
phone 954-509-0911
Email investor.relations@nutrapharm.com
12502 West Atlantic Bvld.
Coral Springs, FL 33071
Shares outstanding 442,185,921 as of May 23,2017.
Shares outstanding 1,233,519,298 as of July 20,2017.
http://www.otcmarkets.com/stock/NPHC/profile
Nutra Pharma Corp. (OTCBB: NPHC) http://www.NutraPharma.com is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. |
ReceptoPharm is an innovative biopharmaceutical drug discovery company developing proprietary therapeutic protein products primarily for the prevention and treatment of viral, autoimmune and neurological diseases in humans, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Pain, and Myasthenia Gravis (MG), and Human Immunodeficiency Virus (HIV). Drug Development The emphasis of ReceptoPharm's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature. » Learn More CRO Services ReceptoPharm offers a full range of contract services catering to start-up and small biotechnology companies. These services include pre-production studies, contract manufacturing services, US & EU regulatory support, and quality systems/GMP certification. ReceptoPharm is a wholly owned subsidiary of Nutra Pharma Corporation. |
Designer Diagnostics is a biotechnology sales and marketing company founded for the sale of diagnostics testkits for infectious diseases. Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon source or those that are hydrophobic. Additionally Designer Diagnostics provides an efficient solution for the rapid identification and sensitivity testing of Tuberculosis (TB). Designer Diagnostics is a wholly owned subsidiary of Nutra Pharma Corporation. |
Cobroxin/Nyloxin TV Commercials and Advertising |
Here is a YouTube clip from 2013 showing the product: |
Nutra Pharma (NPHC.OB) RECENT NEWS | |||||
SOURCE: Nutra Pharma Corporation
|
ADDITIONAL NUTRA PHARMA INFORMATION |
12/10/09 Webinar from Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation:http://a40.video2.blip.tv/5350002509400/Vpoole-NHPCPresentationByCEO594.wmv?bri=11.6&brs=126 |
CHECK OUT THE Nutra Pharma Blog FOR MORE INFO ON THE WORLD MONEYSHOW CONFERENCE! |
|
Nutra Pharma (NPHC.OB) PATENTS |
U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims.U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone.Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa.Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS.Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin.Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol. |
R&D Pipeline | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
During our second quarter of 2015 and thereafter, the following has occurred:
On April 15, 2015 we provided an update regarding plans to market Nyloxin® through S.Zhaveri Pharmakem for distribution throughout India. The update stated that our management had been working in Mumbai throughout the week to finalize plans for the national rollout of Nyloxin®.
On April 20, 2015, our stockholders voted at a special meeting of the shareholders held in Coral Springs, Florida to approve a one-for-forty reverse stock split of our issued and outstanding shares of common stock. Under the adopted proposal, each forty shares of our presently issued and outstanding Common Stock as of the close of business on the effective date was converted automatically into one share of our post-Reverse Split Common Stock. Fractional shares and "odd lots" were rounded up to the nearest whole share. The Reverse Split did not change the number of authorized shares of our Common Stock. The principal effect of the Reverse Split was the reduction in the number of shares of Common Stock issued and outstanding, from 1,510,950,321 shares as of March 6, 2015 to 39,123,758 shares after the Reverse Split was deemed effective. The Reverse Split affected all of our shareholders uniformly and did not affect any shareholder’s percentage ownership interest in Nutra or any shareholder’s proportionate voting power. Per share and weighted average amounts have been retroactively restated in the accompanying financial statements and related notes to reflect this stock split.
On April 22, 2015 we announced that we had engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for Nyloxin®.
On April 30, 2015 we announced that we had received notification of the acceptance of Nyloxin® by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China.
On May 14, 2015 we announced that we had engaged the Nature's Clinic to begin the process of regulatory approval of our Company's Over-the-Counter pain drug, Nyloxin® for marketing and distribution in Canada. The Nature’s Clinic has already begun setting up their Chatham, Ontario warehouse and expect to complete the approval process to begin distributing Nyloxin® by the end of the year.
On May 26, 2015 we announced that we had engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA"). The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M. In order to create the application, RPI-78M needed to meet several key criteria. This included preclinical data in support of the drug that provided a reasonable rationale for the treatment of the disease based on its potential ability to treat the symptoms of multiple sclerosis. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The Orphan Drug Act of 1983 is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as those affecting fewer than 200,000 Americans at any given time. The designation of RPI-78M as an Orphan Drug would provide Nutra Pharma with a 7-year period of market exclusivity in the U.S. upon approval of the drug, as well as tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The decision to proceed with an Orphan Drug Designation submission is part of Nutra Pharma's plan to move forward with the preparation of an Investigative New Drug Application.
On June 9, 2015 we announced that we had entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc. (NLS): Nationwide Laboratory Services, Inc. operates as a clinical diagnostics laboratory, performing routine and specialty human diagnostics. The company also offers clinical trial services, such as specimen and special handling requirements, status of test results, turnaround time, testing, participants test results, channeling calls to technical or professional personnel, communicating specimen issues, notifying investigational site of critical calls, and telephone support with data management training services; and courier tracking services. The collaboration provides NLS with the use of our lab space and equipment and provides us with lab and clinical personnel as well as cost-savings on rent and utilities.
On June 23, 2015 we announced that we had completed a series of projects to update and expand the facilities that house the Asian cobras utilized for the production of Nyloxin®. We also announced the addition of 100 snakes to the existing milking line to increase venom production for the upcoming international orders from India and China.
On June 30, 2015 we announced that we had engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in our strategies for maximizing shareholder value through its full scope of investment banking services.
On July 10, 2015, SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, announced it has initiated coverage of Nutra Pharma Corporation with a Price Target of $0.53 per share.
On July 15, 2015 we announced that we had filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children. This represents the first such filing for the company.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |